The Bull Rankings scorecard — our quality-growth score is 47.3 / 100, built from three pillars scored 0–100: Quality 37, Growth 92, Value 31 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 30% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
TEAM is a growth‑only play that the market is already pricing at a very high free‑cash‑flow (FCF) growth rate. Our Bull Rankings model assigns a 47.3/100 quality‑growth score, with Growth at 92, Quality at 37, and Value at 31. The single sharpest argument for TEAM today is that the Growth pillar dominates the story: revenue is up 26% YoY, and the reverse‑DCF implies a 30% per‑year FCF growth (in year one, slowing to 3% a year by year ten). That implied rate is modestly above the current revenue growth, meaning the price assumes today’s pace holds or quickens slightly. If the company can sustain that FCF growth, the price is justified; if not, the market is over‑optimistic.
What the business actually is
Atlassian sells a suite of collaboration software that stitches together work across teams. Core products—Jira, Confluence, Trello, Bitbucket, and Loom—serve software developers, product managers, and enterprise teams. The company also offers Collections, curated sets of apps built on its cloud platform that solve cross‑functional workflows. Customers range from mid‑market firms to large enterprises that rely on these tools to coordinate strategy, service, and product development. The revenue engine is driven by subscription licensing and cloud services, with a strong focus on expanding within existing accounts.
Why it can (or can't) keep compounding
The moat lies in switching costs and platform depth. Jira and Confluence are entrenched in development pipelines; once a team adopts them, switching costs rise sharply. The breadth of the product portfolio—Jira Service Management, Rovo, Compass, and Talent—creates a single‑source ecosystem that locks in users across functions. Competitors cannot replicate this breadth quickly because they lack the integrated data layer and the developer‑friendly APIs that Atlassian provides. Returns on capital are modest, with a debt‑to‑equity of 1.16 and a negative profit margin of –0.8%, but the company’s high revenue growth offsets margin pressure. The Quality pillar at 37 is weak: strong cash generation is offset by losses, and the negative ROE of –5.1% signals that profitability remains a challenge.
The valuation question
At a current price of $192.77, the price‑to‑sales ratio sits at 7.4. The analyst consensus 1‑year target of $196.23 is only 2% above today’s price, suggesting that analysts are not expecting a dramatic upside. The reverse‑DCF shows that the stock is priced for 30%/yr FCF growth (in year one, slowing to 3% a year by year ten). In contrast, revenue grew 26% YoY in FY 2026. The implied FCF growth is therefore slightly higher than revenue growth, close enough that our model reads the two as roughly in line. If the company can maintain or exceed that 30% FCF growth, the current valuation would be justified; if it stalls, the price is over‑optimistic.
The bear case
The weakest pillar in our model is Value at 31. A low value score signals that the stock is expensive relative to peers. The negative profit margin of –0.8% and ROE of –5.1% reinforce that the business is still loss‑making. If the company cannot turn margins positive, the high growth assumptions become untenable. A concrete trigger would be a drop in revenue growth below 20% or a margin decline to –5% or worse, which would invalidate the 30% FCF growth premise embedded in the price.
What would change our mind
- Revenue growth falling below 20% would erode the 30% FCF growth assumption and push the valuation lower.
- Profit margin slipping to –5% or deeper would signal that the cost structure is unsustainable, weakening the growth thesis.
- Debt‑to‑equity rising above 1.5 would increase financial risk and reduce the company’s ability to invest in product expansion.
If any of these thresholds are breached, the current price would appear overvalued, and the thesis would shift toward caution.